With prescription therapies at the center of more Americans health care, these medications have become invaluable. costs. Despite the 1.6% 1.2% 0.
|
|
- Deirdre Hunter
- 5 years ago
- Views:
Transcription
1 Rx spending up, but challenges remain By Richard Monks No products play a greater role in setting drug stores and community pharmacies apart from other retailers than prescription drugs. One % prescription growth of the most important factors in securing pharmacies increasingly important role in the country s healthcare system, prescription medications define what these stores are all about. With prescription therapies at the center of more Americans health care, these medications have become invaluable to the battle to control the nation s healthcare costs. Despite the NOMINAL AND PER CAPITA DISPENSED PRESCRIPTION GROWTH % 1.3% 3.2% 2.3% 4.5% 3.5% 1.7% 2.7% 1.1% 2.1% TRx TRx per capita 1.1% 0.7% 1.2% 1.6% 0.9% added significance prescription drugs are having in patients lives, they continue to account for only a small percentage of overall healthcare spending in the United States. According to the Pharmaceutical and Research Manufacturers Association, prescription drugs account for less than 10% of total healthcare spending. In its report Medicine use and shifting costs of health care: A review of Continued on page 58 IT IS PENNY-WISE AND POUND-FOOLISH TO FOCUS SOLELY ON THE PRICE OF A NEW MEDICINE WHILE COMPLETELY IGNORING THE VALUE IT PROVIDES TO PATIENTS AND THE HEALTHCARE SYSTEM BROADLY. John Castellani, president and CEO, Pharmaceutical Research and Manufacturers of America COMPONENTS OF CHANGE IN TOTAL SPENDING* 0.2% 1.2% 0.3% -0.1% 0.5% Generics New brands Protected brands price Protected brands value Loss of exclusivity Source: IMS Health, NPA, January 2014; U.S. Census Bureau NOMINAL AND REAL PER CAPITA SPENDING GROWTH % 9.3% Nominal medicines spending growth Real per capita medicines spending growth % spending growth U.S. 5.1% 5.6% 1.2% 4.9% 3.8% 1.9% -0.2% 5.3% 5.2% 3.1% 3.4% 1.1% 4.0% -1.0% 3.2% 1.0% % -3.5% Source: IMS Health, National Sales Perspectives, January 2014; U.S. Census Bureau July 2013; Economist Intelligence Unit, November * In billions Source: IMS Health, National Sales Perspectives, January AUGUST 26, 2014 DRUGSTORENEWS.COM
2 AFTER MANY YEARS OF SLOWING GROWTH, LARGELY DUE TO PATENT EXPIRIES, A RETURN TO GROWTH FOR MEDICINES IS LOOKED AT WITH CAUTION BY PAYERS AND POLICY MAKERS ALIKE. Murray Aitken, executive director, IMS Institute for Healthcare Informatics Continued from page 56 the use of medicines in the United States in 2013, the IMS Institute for Healthcare Informatics found that spending on prescription medications hit $329.2 billion last year, up 3.2% nominally and up from the 1% decrease in The report noted that the uptick in drug spending represents a 1% hike on a real, per-capital basis, and that per capita drug usage increased 0.9%. The authors of the IMS report noted that most industry observers remain cautious that last year s spending increase is a sign of things to come. Rather, they have suggested that the rise in drug spending in 2013 may be a one-time thing. After many years of slowing growth, largely due to patent expiries, a return to growth for medicines is looked at with caution by payers and policy-makers alike, IMS executive director Murray Aitken said in his introduction to the report released in April. Despite this view, little has changed in the dynamics of medicines spending, and in fact, the key elements of long-term savings and restraint in healthcare spending are clear. IMS said that while more people getting prescription insurance under the Affordable Care Act played a role in driving up drug spending last year after 2012 saw the largest spending decline ever, a number Continued on page 60 DISPENSED PRESCRIPTIONS BY DISPENSING LOCATION* CHANNEL RETAIL 3, , , , ,637.0 Chain stores 2, , , , ,132.0 Independent Food stores Mail service INSTITUTIONAL Long-term care TOTAL U.S. MARKET 4, , , , ,953.0 * In millions Source: IMS Health, National Sales Perspectives, National Prescription Audit, January 2014 NON-DISCOUNTED SPENDING* BY DISPENSING LOCATIONS CHANNEL RETAIL $236.2 $228.9 $236.0 $226.8 $214.9 Chain stores Mail service Independent Food stores INSTITUTIONAL $93.1 $90.2 $92.4 $88.9 $85.3 Clinics Non-federal hospitals Long-term care HMO Home health care Federal facilities Miscellaneous TOTAL U.S. MARKET $329.2 $319.1 $328.5 $315.7 $300.1 * In billions Source: IMS Health, National Sales Perspectives, National Prescription Audit, January 2014 NEW MOLECULAR ENTITIES LAUNCHED IN THE UNITED STATES, New mechanism Orphan Existing mechanism Source: IMS Institute for Healthcare Informatics, February AUGUST 26, 2014 DRUGSTORENEWS.COM
3 Continued from page 58 of other factors were equally important in the turnaround. For instance, fewer patent expirations and the development of innovative new medicines led many patients to rely on higher-priced drugs. Patent expirations last year resulted in $19 billion less in medicine spending, compared with a $29 billion reduction in 2012, IMS said. At the same time, 36 new molecular entities targeting such diseases as cancer, hepatitis C and HIV launched in 2013, the largest number in a decade. And, while healthcare reform has led more patients to utilize a wider range of wellness and preventive services and driven more people into the prescription market, the dynamics of the healthcare system during the lead up to the ACA s full implementation actu- Continued on page 62 DRIVERS OF LOSS OF EXCLUSIVITY NEGATIVE BRAND GROWTH IN U.S. BILLIONS 2012 $-2.6 $ $-3.1 $-2.0 $-12.7 PERCENT SHARE OF PRESCRIPTIONS Unbranded generics Branded generics 84% 86% 72% 74% 78% 80% 67% 57% 60% 63% 46% 50% 54% 58% 63% 66% 70% 73% 77% 80% 11% 10% 9% 9% 9% 8% 8% 7% 7% 6% Source: IMS Health, Naitonal Prescription Audit, January 2014 Spending in leading therapy areas THERAPY AREA SALES* % GROWTH Oncology $ % Antidiabetes Mental health Respiratory Pain Autoimmune $-15.6 $-1.5 Lipid regulators Antihypertensives HIV Antivirals Multiple sclerosis Products with >$1 billion in pre-expiry spending in each expiry cohort 2013 Expiries Cymbalta 2012 Expiries Plavix, Singulair, Seroquel, Lexapro, Actos, Diovan HCT* Anti-ulcerants ADHD Dermatologicals Antibacterials Nervous system disorders Anticoagulates Expiries Lipitor Zyprexa 2010 Expiries Tricor Eloxatin Vaccines Sex hormones Opthalmology Hormonal contraceptives * Diovan lost patent protection in 2012 but has failed to face generic competition, while the fixed-dose combination with hydrochlorothiazide has faced generic competition Source: IMS Health, Naitonal Sales Perspectives, December 2013 Specialty *In billions Source: IMS Health, National Sales Perspectives, January 2014 Traditional 60 AUGUST 26, 2014 DRUGSTORENEWS.COM
4 THERAPY AREAS ASSOCIATED WITH DECLINING COSTS, SUCH AS HYPERTENSION AND MENTAL HEALTH, SAW INCREASING VOLUME, PERHAPS RELATED TO REDUCTIONS IN PATIENT OUT-OF-POCKET COSTS. Murray Aitken, executive director, IMS Institute for Healthcare Informatics SELECTED THERAPY AREAS WITH LARGEST POSITIVE AND NEGATIVE CONTRIBUTIONS TO TRx GROWTH 2013 TRx in millions Continued from page 60 ally contributed to the increased spending, as patients with insurance paid higher out-of-pocket expenses in the form of deductibles and co-insurance last year. IMS noted, however, that since the start of 2014, prescription co-payments have come down to less than growth % TRx 1.1% 1.7% 5.9% 4.6% -1.0% -1.4% -1.0% $5 for more than half of all prescriptions filled. IMS pointed out that growing pressure to keep costs down could lead to even less growth Nervous Anti- Mental Lipid going forward. Pain Antibacterials system Hormonal hypertensives health regulators disorders contraceptives Researchers found that price increases for branded products added $4 billion more in spending growth Source: IMS Health, Naitonal Prescription Audit, January 2014 Continued on page 64 TOP 20 DRUGS BY TRx DRUG MAT APRIL* 2014 MAT APRIL* 2013 HYCD/APAP Lisinopril Levothyroxine SOD Simvastatin Amlodipine Besy Omeprazole (Rx) Atorvastatin Ca Metformin Hcl Amoxicillin Hydrochlorothiazid Alprazolam Azithromycin Gabapentin Furosemide Metoprolol Tart Sertraline Hcl Tramadol Hcl Fluticasone Prop Citalopram HBR Metoprolol Succin * In billions Source: IMS Health, IMS National Prescription Audit Plus, TM, April 2014 TOP 20 THERAPIES BY 2013 SALES THERAPIES 2013 SALES 2012 SALES 2013 % SHARE % GROWTH Oncology $27.9 $ % 9.2% Antidiabetes Mental health Respiratory Pain Autoimmune Lipid regulators Antihypertensives HIV antivirals Multiple sclerosis Anti-ulcerants ADHD Dermatologicals Antibacterials Nervous system disorders Anticoagulants Vaccines excl. flu Sex hormones Ophthalmology Hormonal contraceptives All other therapies * In billions Source: IMS Health, IMS National Sales Perspectives (retail and non-retail),tm, March AUGUST 26, 2014 DRUGSTORENEWS.COM
5 Continued from page 62 last year than in However, other market forces off-invoice discounts and rebates resulted in net price growth being essentially flat from 2012 to While spending on biologics and specialty drugs is outpacing the broader prescription market, especially in retail and mail-order pharmacies, the vast majority of spending on medicines continues to come from traditional small-molecule pills dispensed through retail pharmacies. IMS data showed that retail pharmacies accounted for 71.7% of prescription sales nationwide last year with pharmacies in drug stores, discount stores and supermarkets, as well as mail-order operations, dispensing more than 91% of the nearly 4.2 billion prescriptions filled last year. A growing number of those prescriptions are being filled with generics another factor that many say is contributing to the slowdown in drug spending. IMS reported that 86% of the prescriptions dispensed in 2013 were filled with a generic. A decade ago, only slightly more than half of all prescriptions were filled with generics. The continued increase in generic utilization has been good news for both retailers and patients. While carrying pricepoints well below their brandname equivalents, generic drugs provide pharmacies with higher margins. For patients and insurers, these medications are more affordable, leading many to suggest that wider use of generics is making it easier for patients to afford their medicines and driving up adherence rates. IMS reported that patients filled an average of more than 12 prescriptions at retail last year, up nearly 2% over However, people older than 65 years filled an average of 28 prescriptions annually at retail, down slightly from The disease states treated by those prescriptions had a positive impact on prescription growth last year, the report said, with two of the largest therapeutic classses antihypertensives and medicines to treat mental health issues contributing to the spike in the number of prescriptions dispensed and helping to curb runaway healthcare spending. Therapy areas associated with declining costs, such as hypertension and mental health, saw increasing volume, perhaps related to reductions in patient out-of-pocket costs, Aitken and his colleagues said. The report noted that that an ongoing shift in the types of medicines being prescribed is helping sales move forward. Spending on biologics and specialty drugs, for instance, grew by 11% to $73 billion in 2013, IMS said, while significant innovation in diabetes and a handful of other therapies helped those ar- Continued on page 66 TOP 20 CORPORATIONS BY Rx VOLUME CORPORATION MAT APRIL* 2014 MAT APRIL* 2013 Teva Mylan Actavis Novartis Endo International Lupin Laboratories Amneal Pharm Pfizer Zydus Cadila Aurobindo Dr. Reddy s Lab Boehringer Ingelheim Apotex Mallinckrodt Hetero Drugs Daiichi Sankyo AstraZeneca Sun Pharma GlaxoSmithKline Abbott * In billions Source: IMS Health, IMS National Prescription Audit Plus, TM, April 2014 TOP THERAPEUTIC CLASSES BY DISPENSED PRESCRIPTIONS THERAPIES Antihypertensives Mental health Pain Antibacterials Lipid regulators Antidiabetics Nervous system disorders Anti-ulcerants Respiratory Antithyroid Dermalotogicals Hormonal contraception ADHD Anticoagulants Vitamins and minerals Corticosteroids GI products Nasal preps, topical Other cardiovasculars Sex hormones TOTAL U.S. MARKET 4, , , , ,953.0 * In millions Source: IMS Health, National Prescription Audit, January AUGUST 26, 2014 DRUGSTORENEWS.COM
6 Continued from page 64 eas grow by 11% to $37 billion. The largest amount of spending, $128 billion, was in therapy areas with limited innovation or patent expirations. Spending in those areas, IMS said, grew by 7%. Meanwhile, price increases on protected brands contributed $20 billion to growth in 2013, up from $15.6 billion a year earlier. The rising cost of prescription drugs has rankled some critics of the pharmaceutical sector who question why the cost of medications is increasing at a rate nearly twice that of inflation. The growing use of biologics and specialty drugs has only added fuel to that fire and caused many Americans to fear having to shell out more in pharmacy co-pays in coming years. According to a study released last month, 57% of the 2,010 people polled reported that they are very concerned they will not be able to afford specialty medicines in the future, and another 35% were somewhat concerned about their ability to afford specialty drugs. The same poll, however, found that current prescription pricing sits well with consumers, as 38% of respondents said they were very satisfied with prescription drug prices and another 40% were somewhat satisfied. John Rother, chief executive of the National Coalition on Health Care, which sponsored the study, said that while the findings indicate that people feel the system has been working, and prescription insurance has helped them absorb the cost of their medications, they are fearful about where drug pricing is headed. One drug in particular has been at the heart of the growing concern about runaway drug pricing. Many of the patients and groups who have voiced concern over the direction that prices are headed point to Sovaldi, Gilead Sciences hepatitis C treatment that costs $84,000 for a 12-week treatment, or $1,000 a day. The drug maker and some health economists contend that the cost is justified because the drug has an extremely high cure rate and alternative Continued on page 68 PERCENT CHANGE IN HOSPITAL ADMISSIONS AND OFFICE VISITS Office visits Inpatient via ER Scheduled inpatient ER Outpatient -14.6% -4.2% -0.8% -3.2% -0.5% -0.6% 2.7% 3.5% 2.4% 1.8% 0.1% 3.2% % 6.2% 10.5% Source: IMS Health, National Disease and Therapeutic Index, IMS Hospital CDM, December 2013 TOP MEDICINES BY DISPENSED PRESCRIPTIONS DRUG 2013* 2012* 2011* 2010* 2009* Acetaminophen/hydrocodone Levothyroxine Lisinopril Metoprolol Simvastatin Amlodipine Metformin Omeprazole Atorvastatin Albuterol Amoxicillin Hydrochlorothiazide Alprazolam Azithromycin Fluticasone Furosemide Gabapentin Sertraline Zolpidem Tramadol Citalopram Prednisone Acetaminophen/oxycodone Ibuprofen Pravastatin TOTAL U.S. MARKET 4, , , , ,953.0 * In millions Source: IMS Health, National Prescription Audit, December AUGUST 26, 2014 DRUGSTORENEWS.COM
7 Continued from page 66 treatments, notably liver transplants, can be more expensive. Sovaldi, they said, could be a sign of what may lie ahead for all prescription medicines as more specialty drugs make their way onto the market. The National Coalition on Health Care poll found that while only 1% of those surveyed said they had taken a specialty drug during the previous year, 29% said they had not taken a medicine due to cost and 51% believed the cost of prescription drugs greatly affects insurance premiums. Meanwhile, 85% of those polled said while it was critical that drug makers continue research into finding treatments for cancer and the other diseases treated by biologics and specialty medicines, pharmaceutical companies need to become more efficient to keep prices down. Only 15% believe society should be prepared to pay whatever these medicines cost. Advocates for the country s drug companies say the high cost of cuttingedge medicines is warranted in light of the greater savings these drugs can bring to the healthcare system. It is penny-wise and pound-foolish to focus solely on the price of a new medicine while completely ignoring the value it provides to patients and the healthcare system broadly, PhRMA president and CEO John Castellani said last month. The increased attention on the cost of new medicines is being fueled by the fact that we have an outdated insurance model that is forcing patients to pay an ever-growing share of their prescription drug costs. Insurers are increasingly imposing unprecedented costsharing on patients that deters them from utilizing the medicines they need to manage or even cure their disease while covering the vast majority of costs of more expensive hospitalizations and services these medicines could prevent SPENDING (IN U.S. BILLIONS) BY THERAPY SEGMENT AND % GROWTH OVER 2012 $ % $ % $ % $ % $ % Primary care with limited innovation and limited LOE Primary care with significant LOE Specialty with recent innovation Primary care wiht significant innovation Other largely specialty with limited innovation Source: IMS Health, Naitonal Sales Perspectives, January 2014 TOP MEDICINES BY NON-DISCOUNTED SPENDING DRUG 2013* 2012* 2011* 2010* 2009* Abilify $6.5 $5.7 $5.3 $4.6 $4.0 Nexium Humira Crestor Cymbalta Advair Diskus Enbrel Remicade Copaxone Neulasta Rituxan Lantus SoloSTAR Spiriva Handihaler Atripla Januvia Avastin Lantus OxyContin Lyrica Epogen Celebrex Truvada Diovan Herceptin Gleevec TOTAL U.S. MARKET $329.2 $319.1 $328.5 $315.7 $300.1 * In billions Source: IMS Health, National Sales Perspectives, January AUGUST 26, 2014 DRUGSTORENEWS.COM
8 NEW MOLECULAR ENTITIES LAUNCHED IN 2013 Source: IMS Institute for Healthcare Informatics, Medicine Use and Shifting Costs of Healthcare 70 AUGUST 26, 2014 DRUGSTORENEWS.COM
9 OTHER NEW MEDICINE LAUNCHES IN 2013 Source: IMS Institute for Healthcare Informatics, Medicine Use and Shifting Costs of Healthcare 72 AUGUST 26, 2014 DRUGSTORENEWS.COM
10 NEW BRAND SPENDING* TOP 10 Rx COMPANIES TOP 10 Rx PRODUCTS Traditional Other specialty Oncology Multiple sclerosis $6.2 $0.5 $0.9 $4.8 $7.3 $0.1 $0.5 $0.9 $6.0 $10.4 $0.6 $1.7 $2.6 $1.9 $6.3 $11.1 $10.9 $0.9 $3.4 $4.1 $1.8 $2.1 $3.6 $ * In billions Source: IMS Health, NPA Market Dynamics, January 2014 PAYMENT TYPE Commercial third-party PERCENT DISPENSED Rx BY PAYMENT 57.0% 58.6% 61.3% 61.6% 62.9% Medicare Part D 26.0% 23.7% 20.6% 19.8% 19.9% Medicaid 9.0% 9.4% 9.5% 9.6% 8.3% Cash 8.0% 8.3% 8.6% 9.0% 8.9% TOTAL U.S. MARKET 4,208 4,139 4,022 3,995 3,953 Source: IMS Health, National Prescription Audit, XPonet, PlanTrak, January 2014 COMPANY SALES MAT APRIL 2014* % GROWTH Novartis $ % Astrazeneca Pfizer Roche Merck & Co Teva Amgen Johnson & Johnson Lilly GlaxoSmithKline TOTAL TOP 10 $ % * In billions, prescription drugs only Source: IMS Health, IMS National Sales Perspectives (retail and non-retail), TM, April 2014 TREATED PATIENTS IN SELECTED THERAPIES* Hypertension Cholesterol Antidepressants Anti-ulcerants Narcotics Antidiabetes Thyroid Anti-epileptics Contraceptives Respiratory Anticoagulants ADHD Insomnia Benign prostate hyperplasia Antipsychotics Osteoporosis Overactive bladder Parkinson s Migraine Alzheimer s DRUG SALES MAT APRIL 2014* % GROWTH Abilify $ % Nexium Humira Crestor Advair Diskus Enbrel Remicade Cymbalta Copaxone Neulasta TOTAL TOP 10 $ % * In billions Source: IMS Health, IMS National Sales Perspectives (retail and non-retail), TM, April * In millions Source: IMS Health, NPA Market Dynamics, January MEDICINES SPENDING AND GROWTH SEGMENTATION COMPARISON Brands: 71% / 1.9% Traditional retail and mail: 56% / 0.9% Total Market: $329B / 3.2% Traditional non-retail: 14% / 1.0% Branded generics: 12% / 3.1% Specialty retail and mail: 15% / 12.6% Generics: 17% / 9% Small molecules: 72% / 0.1% Biologics: 28% / 9.6% Specialty non-retail: 14% / 5.4% Orals: 52% / -1.3% Injectables: 29% / 7.3% Other: 19% / 10.2% Retail: 53% / 3.2% Mail: 19% / 3.2% Non-retail: 28% / 3.2% Source: IMS Health, National Sales Perspectives, January AUGUST 26, 2014 DRUGSTORENEWS.COM
11 PERCENT OF RETAIL PRESCRIPTIONS BY OUT-OF-POCKET COSTS, U.S. $, % 0.1% 0.1% 0.7% 2.3% 2.8% 2.1% 3.2% 5.5% 4.2% 7.2% 2.4% 4.0% 5.2% 5.6% 9.6% 13.3% 14.4% 34.8% ONCOLOGY NEW MOLECULAR ENTITIES LAUNCHED IN THE U.S., Cometriq, Gazyva, Gilotrif, Iclusig, Imbruvica, Kadcyla, Mekinist, Pomalyst, Tafinlar, Xofigo 10 Bosulif, Erivedge, Inlyta, Kyprolis, Perjeta, Stivarga, Synribo, Voraxaze, Xtandi 9 Adcetris, Caprelsa, Erwinaze, Jakafi, Xalkori, Yervoy, Zelboraf, Zytiga 8 Folotyn, Halaven, Istodax, Jevtana, Provenge 5 Arzerra, Firmagon, Votrient 3 Treanda 1 Ixempra, Tsaigna, Torisel, Tykerb 4 Arranon, Dacogen, Revlimid, Sprycel, Sutent, Vectibix, Zolinza 7 Clolar, Nexavar % 2004 Alimta, Avastin, Erbitux, Plenaxis, Tarceva, Vidaza 6 Source: IMS Institute for Healthcare Informatics, February 2014 RETAIL PRESCRIPTIONS BY AGE 25.9% Share of population Share of Rx Change in Rx per capita Prescriptions per capita Age 51.6% % 3.7% 8.9% % 61.0% % 10.0% 22.4% % % 19.5% 30.7% 19.2 National Average % 16.4% 20.1% % 4.2% 1.0% 10.0% 25.4% 31.9% % Total retail % of total 100% Commercial 60.7% Medicare Part D 26.2% Medicaid 13.1% No co-pay $0.01-$5.00 $5.01-$10.00 $10.01-$20.00 $20.01-$30.00 $30.01-$70.00 $ Source: IMS Health, Xponent PlanTrak co-pay, December % 24.9% 8.5% 4.2 Source: IMS Health, Xponent National, January 2014; U.S. Census Bureau 76 AUGUST 26, 2014 DRUGSTORENEWS.COM
12 PERCENTAGE OF WORKERS BY EMPLOYER-BASED INSURANCE TYPE, EMPLOYER-BASED INSURANCE WITH DEDUCTIBLES, % 45% 57% $1,600 $1,400 72% 78% 90% 80% 70% $1,200 $1,135 60% % % 20% PPO HMO and other types HDHP/SO Source: Kaiser Family Foundation, Kaiser Employer Health Benefits 2013 Annual Survey, January 2014 $1,000 $800 $600 $400 52% $584 10% 38% Average deductible % of workers with deductible % of workers with deductible of $, % 40% 30% 20% 10% 0% Source: Kaiser Family Foundation, January 2014 PERCENT OF RETAIL PRESCRIPTIONS ABANDONED AND REJECTED 15% 10% 5% Patient abandonment Payer rejection DISTRIBUTION OF PAYER REJECTION REASONS IN SELECTED CLASSES 5.3% 19.9% 30.8% 0% Acne Anticoagulant Antidepressant Atypical antipsychotic Cholesterol Diabetes Gout HIV Obesity Proton-pump inhibitors Rheumatoid arthiritis Sedative Average 11.7% 12.0% 20.4% Quantity limits PA required All other Not covered Step edits Refill too soon Source: IMS Health, Formulary Impact Analyzer; December 2013 Source: IMS Health, Formulary Impact Analyzer; December AUGUST 26, 2014 DRUGSTORENEWS.COM
13 PRIMARY CARE WITH LIMITED INNOVATION AND LIMITED LOSS OF EXCLUSIVITY 2013 therapy segment spending and growth SELECTED NEWER GENERATION DIABETES BRANDS New to brand and continuing prescriptions 10.4% New to brand Rx by type of payment Average out-of-pocket cost $73.26 $64.97 $53.47 $128 Bn / 6.5% 89.6% 85.7% 14.3% $25.00 $13.33 $5.00 Drivers of segment spending and growth Protected brands - Volume -1.3% New to brand Rx Continuing TRx Without coupon With coupon With coupon Without coupon High Average Low Source: IMS National Prescription Audit, IMS Consulting Group, company/product websites PERCENT OF RETAIL-DISPENSED PRESCRIPTIONS BY OUT-OF-POCKET COSTS, U.S. $ 31.7% 33.8% Protected brands - Pricing 4.3% 23.2% 21.7% 23.3% 21.6% LOE impact -1.9% New brands 0.2% 10.0% 9.6% Generics 5.1% 4.6% 4.0% 6.2% 5.5% 2.4% 2.3% % Source: IMS Health, National Sales Perspectives, January 2014 No co-pay $0.01- $5.00 $5.01- $10.00 $ $20.00 $ $30.00 Prescription out-of-pockets costs (U.S.$) $ $70.00 $ Source: IMS Health, Xponent PlanTrak Co-Pay, December AUGUST 26, 2014 DRUGSTORENEWS.COM
14 PRIMARY CARE WITH SIGNIFICANT LOSS OF EXCLUSIVITY 2013 therapy segment spending and growth $79.6 Bn / -10.2% RETAIL DISPENSED PRESCRIPTIONS BY OUT-OF-POCKET COSTS, U.S. $ 2.3% 5.5% 4.0% 9.6% 29.9% 21.6% 22.1% Drivers of segment spending and growth Protected brands - Volume Protected brands - Pricing -1.1% 6.6% 33.8% 9.4% 12.9% LOE impact -15.6% New brands 1.4% Generics -1.5% % Source: IMS Health, National Sales Perspectives, January % Share of TRx 0.0% 16.7% 9.1% Share of total out-of-pocket costs No co-pay $0.01-$5.00 $5.01-$10.00 $10.01-$20.00 $20.01-$30.00 $30.01-$70.00 $ Source: IMS Health, Xponent PlanTrak co-pay, December 2013 SAVINGS ON PRESCRIPTIONS WITH NO CO-PAY FOR COMMERCIALLY INSURED IN 2013 Increase in number of prescriptions with no co-pay (in millions) Incremental 2013 savings in patient out-of-pocket costs (U.S. $ millions) $24.8 $21.6 $483.3 $27.7 $19.5 $211.6 Contraceptives Antihypertensives Mental health Cholesterol Respiratory Total others Source: IMS Health, Xponent PlanTrak Co-Pay, December AUGUST 26, 2014 DRUGSTORENEWS.COM
15 SPECIALTY WITH RECENT INNOVATION 2013 therapy segment spending and growth PRIMARY CARE WITH SIGNIFICANT INNOVATION 2013 therapy segment spending and growth $73.3 Bn / 11.4% $36.5 Bn / 11.1% Drivers of segment spending and growth Drivers of segment spending and growth Protected brands - Volume 0.3% Protected brands - Volume 0.2% Protected brands - Pricing 7.0% Protected brands - Pricing 7.0% 11.9% LOE impact -2.1% LOE impact -5.5% New brands 5.5% New brands 3.0% Generics 0.7% Generics 1.5% % % Source: IMS Health, National Sales Perspectives, January 2014 Source: IMS Health, National Sales Perspectives, January AUGUST 26, 2014 DRUGSTORENEWS.COM
16 TRENDS IN HOSPITAL ADMISSIONS BY PAY TYPE* ER Oupatient Inpatient Scheduled inpatient Inpatient via ER ER commercial ER Medicaid ER Medicare Outpatient commercial Outpatient Medicaid Outpatient Medicare *In millions Source: IMS Health Hospital CDM, December 2013 PERCENT CHANGE IN OFFICE VISITS BY PHYSICIAN TYPE AND PATIENT AGE IN 2013 Total -0.7% 2.7% 4.9% Seniors (65+) 2.6% 6.7% 9.5% Adults (26-64) -2.1% 2.2% 5.9% Young adults (19-25) -2.7% 1.0% 3.4% Children (0-18) -1.1% 0.0% 0.2% Total Specialist Primary care Source: IMS Health, National Disease and Therapeutic Index, December AUGUST 26, 2014 DRUGSTORENEWS.COM
US pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health
US pharmaceutical market: trends, issues, forecast Doug Long Vice President Industry Relations IMS Health 2006 Strategic management review The World Pharmaceutical Market All reproduction rights, quotations,
More informationPrescription Drugs. Medicare & Medicaid Briefings National Health Policy Forum February 22, Jim Hahn Congressional Research Service
Prescription Drugs Medicare & Medicaid Briefings National Health Policy Forum February 22, 2007 Jim Hahn Congressional Research Service Global and US. Prescription Drug Sales, 1998-2005 $700 $600 559 602
More informationMArch The 2014 Drug Trend Report Highlights
MArch 2015 The 2014 Drug Report Highlights Highest Increase in U.S. Drug Spend Over Past Decade In 2014, the pharmacy landscape underwent a seismic change, and the budgetary impact to healthcare payers
More informationtaking at (Jan. 21, 2016) by Older 2016.pdf).
HSGAC MINORITY STAFF REPORT MANUFACTURED CRISIS How Devastating Drug Increases Are Harming America s Seniors U.S. Senate Homeland Security & Governmental Affairs Committee, Minority Office Page 1 EXECUTIVE
More informationPharmacy Trends and Management Opportunities. Kerry Bendel, R.Ph. Director of Pharmacy Medica
Pharmacy Trends and Management Opportunities Kerry Bendel, R.Ph. Director of Pharmacy Medica September 14, 20 1 Agenda Pharmacy Trend Experience Trend Drivers and Management Opportunities Call to Action
More informationPBS Growth. The changing composition of the PBS. PBS Top 10 drugs in transition. Shifting sands for industry as generic volume soars
PBS Growth The changing composition of the PBS PBS Top 10 drugs in transition Shifting sands for industry as generic volume soars The under co-payment market PBS Update 2014-15 Growth in PBS spending was
More informationTips for Evolving Medicaid Pharmacy Benefits Management (PBM) Programs. June 5, 2015
Tips for Evolving Medicaid Pharmacy Benefits Management (PBM) Programs 1 June 5, 2015 Introductions Mark Steck Pharm.D Independent Consultant, MAXIMUS John J.P. Crouse Vice President, MAXIMUS Market Lead
More informationMarket Distortions from the 340B Drug Pricing Program
Market Distortions from the 340B Drug Pricing Program Adam J. Fein, Ph.D. www.drugchannels.net @DrugChannels The opinions and views expressed in this presentation are those of the author and may not reflect
More informationPharmacy Costs: Can I Make a Difference?
Pharmacy Costs: Can I Make a Difference? Pharmaceutical Market Dynamics What is driving Rx cost up? No New Blockbusters Patent Expirations OTC Market Dynamics Availability Pharmaceutical Companies Unfortunately,
More informationF Y 1 8 U T I L I Z A T I O N R E V I E W 7/1/2017 TO 3/31/2018 L O C K T O N C O M P A N I E S
UNIVERSITY OF ALASKA F Y 1 8 U T I L I Z A T I O N R E V I E W 7/1/2017 TO 3/31/2018 L O C K T O N C O M P A N I E S Premera - Medical L O C K T O N C O M P A N I E S Medical Utilization % Change Norm
More informationHave you been paying for your prescription drugs? Stop!
Dear Valued Medtipster Member: Have you been paying for your prescription drugs? Stop! Free prescription drugs are NOW just a Medtipster ID card away. Follow the steps below to obtain thousands of generic
More informationDRUG TREND REPORT. WellDyneRx ANNUAL 1 2% 34% WellDyneRx. Diabetes MS Oncology Asthma/COPD HIV. Pain/inflammation. High Blood Choles Attention Disorde
WellDyneRx 34% 1 2% Inflammatory Con Diabetes MS Oncology Asthma/COPD High Blood Pressu HIV Pain/inflammation High Blood Choles Attention Disorde Inflammatory Con Diabetes MS Oncology Asthma/COPD High
More informationUnited States For Non-Dependence: An Analysis of the Impact of Opioid Overprescribing in America
United States For Non-Dependence: An Analysis of the Impact of Opioid Overprescribing in America September 26, 2017 USND Report Background This report is the culmination of research to identify and better
More informationThe use of high cost or Nonpreferred Brand drugs is contributing to higher overall costs for your group. Consider the following to reduce costs:
April 22, 2014 Sandy Randall Dear Ms. Randall: Enclosed are 4 th Quarter 2013 reports that analyze the major parameters of drug utilization by Rocky Mountain Health Plans (RMHP) Members within the. Graphs
More informationINSIGHT on the Issues
INSIGHT on the Issues AARP Public Policy Institute Rx Watchdog Report: Drug Prices Continue to Climb Despite Lack of Growth in General Inflation Rate AARP s Public Policy Institute finds that average manufacturer
More informationMedicaid Perspective
Prescription Opioid Fraud and Abuse: Medicaid Perspective Presenter: Gary P. Gilmore, B.S., R.Ph. Director, Analysis & Reporting Office of Clinical Affairs Deputy Director, Pharmacy Program Objectives:
More informationThe Oncology Drug Marketplace: Trends in Discounting and Site of Care
The Oncology Drug Marketplace: Trends in Discounting and Site of Care DECEMBER 2017 PREPARED BY: Aaron Vandervelde avandervelde@thinkbrg.com 202.480.2661 Eleanor Blalock eblalock@thinkbrg.com 202.480.2772
More informationTHE GROWTH OF SPECIALTY PHARMACY
UnitedHealth Center for Health Reform & Modernization THE GROWTH OF SPECIALTY PHARMACY Current trends and future opportunities Issue Brief April 2014 Summary Innovative specialty drugs are providing important
More informationApril 2o14. The 2013 Drug Trend Report Highlights
April 2o14 The 2013 Drug Trend Report Highlights Express Scripts Reports Lowest Specialty Drug Trend Since 2007 In 2013, spending on prescription drugs increased 5.4% after several years of slower-paced
More informationCapitol Insights: A UC Center Sacramento Panel Discussion Soaring Drug Prices: Consumer and Clinician Perspectives and Policy Options
Capitol Insights: A UC Center Sacramento Panel Discussion Soaring Drug Prices: Consumer and Clinician Perspectives and Policy Options UCSF Center for Healthcare Value Philip R. Lee Institute for Health
More informationMedication trends shaping workers compensation. A 2018 update of the prevailing industry influences impacting pharmacy outcomes
Medication trends shaping workers compensation A 2018 update of the prevailing industry influences impacting pharmacy outcomes This page intentionally left blank Trends impacting workers compensation pharmacy
More informationCoventry Health Care of Georgia, Inc.
Coventry Health Care of Georgia, Inc. PRESCRIPTION DRUG RIDER (for High Deductible Health Plans) This Prescription Drug Rider is an attachment to the Coventry Health Care of Georgia, Inc. ( Health Plan
More informationAre Specialty Pharmacy Drugs Worth the Cost? How Companies Can Make Them More Affordable.
Are Specialty Pharmacy Drugs Worth the Cost? How Companies Can Make Them More Affordable. BACKGROUND Your Host: Eric Bricker, MD Co-Founder & Chief Medical Officer - Compass Professional Health Services
More information2016 Drug Trend Report MEDICARE
2016 Drug Trend Report MEDICARE 2016 Drug Trend Report Medicare Introduction 3 Trend analysis 6 Keeping spending increases in check for America s seniors 7 Medicare Advantage Prescription Drug Plan (MAPD)
More informationJPMorgan Investor Meeting
David B. Snow, Jr. Chairman and CEO JoAnn A. Reed Senior Vice President, Finance and CFO Richard J. Rubino,, CPA Senior Vice President, Controller and CAO Robert S. Epstein, M.D., M.S. Senior Vice President,
More informationF Y 1 9 U T I L I Z A T I O N R E V I E W 7/1/2018 TO 9/30/2018 L O C K T O N C O M P A N I E S
UNIVERSITY OF ALASKA F Y 1 9 U T I L I Z A T I O N R E V I E W 7/1/2018 TO 9/30/2018 L O C K T O N C O M P A N I E S Premera- Medical L O C K T O N C O M P A N I E S Medical Utilization % Change Norm FY18
More informationTRENDS IN MANUFACTURER PRICES OF BRAND-NAME PRESCRIPTION DRUGS USED BY OLDER AMERICANS SECOND QUARTER 2006 UPDATE
TRENDS IN MANUFACTURER PRICES OF BRAND-NAME PRESCRIPTION DRUGS USED BY OLDER AMERICANS SECOND QUARTER 2006 UPDATE INTRODUCTION This Data Digest reports on changes in manufacturer prescription drug prices
More informationUnderstanding the Value of Generic Drugs
Understanding the Value of Generic Drugs Generic drugs can help you get the most out of your health care budget. 05.02.306.1 (8/05) Many people believe that when something costs more, it must be of higher
More informationPharmacy Benefit Solutions 2010 Trend Report
Pharmacy Benefit Solutions 2010 Trend Report Here we share pharmacy benefit trend Presenting management our PBM performance trend performance the for the past past year year and a glimpse into the future.
More informationPrescription Benefit Management. Eric Cannon, PharmD, FAMCP
Prescription Benefit Management Eric Cannon, PharmD, FAMCP Agenda Drugs as a Share of Health Spending Top Drugs of 2016 Management Interventions and Strategies Specialty Pharmacy, Generics and Biologics
More informationRecent Surge in FDA Approvals Shakes up the Oncology Promotional Landscape. Perjeta. Stivarga. Marquibo. Bosulif. Xtandi. Krypolis.
Krypolis Bosulif Inlyta Erivedge Xtandi Stivarga Alimta Gleevec Marquibo Perjeta Synribo Zaltrap Recent Surge in FDA Approvals Shakes up the Oncology Promotional Landscape By Bill Bowman, JD What a year
More informationJohn Ansell President, John Ansell Consultancy Thame, UK
Rutgers University Monday 29 September 2014 Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva 1
More informationWalgreens (WAG) Analyst: Juan Fabres Fall 2014
Recommendation: Buy Target Price August 31, 2016: $77.57 1. Reasons for the Recommendation With the acquisition of Alliance Boots in Europe, Walgreens will be the first US pharmacy to operate retail stores
More informationRx Watchdog Report Trends in Manufacturer Prices of Generic Prescription Drugs Used by Medicare Beneficiaries 2003 to 2007
Rx Watchdog Report Trends in Manufacturer Prices of Generic Prescription Drugs Used by Medicare Beneficiaries 2003 to 2007 by David J. Gross AARP Outreach & Service Stephen W. Schondelmeyer PRIME Institute,
More information2017 Drug Trend Report Commercial Medicare Medicaid Exchanges
2017 Drug Trend Report Commercial Medicare Medicaid Exchanges Leading the way for patients and plans Our clients place a great deal of trust in Express Scripts. They ask us to care for their plan members
More informationClinical Therapeutic Intelligence Report: Year in Review
Clinical Therapeutic Intelligence Report: Year in Review Last year marked a productive year for oncology drug research and development with ten new oncology drugs coming to market two of which were granted
More informationHow Mail-Servi. Prepared for
How Mail-Servi ice Pharmacies Will Save $46.6 Billion Over the Next Decade and the Cost of Proposed Restrictions Prepared for February 2012 Table of Contents I. Executive Summary... 3 Major Findings on
More informationJefferies Healthcare Conference. June 2016
Jefferies Healthcare Conference June 2016 Today s Speakers John Figueroa Chief Executive Officer Vic Breed Chief Financial Officer Joined Genoa in July 2014 Previously served the dual roles of CEO of Apria
More informationMail Order Is Not For Everyone!
Mail Order Is Not For Everyone! Face to face patient counseling by pharmacists can have a powerful impact on long term health care costs and quality. So, the way health plan sponsors promote mail and generics
More informationMediscor Medicines Review 2011
Mediscor Medicines Review 2011 Mediscor Client Workshop 2012 28 August 2012 Presented by: Madelein Bester Benefit Management Mediscor PBM Content Background of the report Overall trends Expenditure per
More informationGenerics. Lead with. P r e s c r i p t i o n S t e p T h e r a p y P r o g r a m
Lead with Generics P r e s c r i p t i o n S t e p T h e r a p y P r o g r a m WWW.BCBSLA.COM 04HQ3972 5/09 Blue Cross and Blue Shield of Louisiana incorporated as Louisiana Health Service & Indemnity
More informationAlex Azar Secretary, Department of Health and Human Services
February 28, 2018 Alex Azar Secretary, Department of Health and Human Services Dear Secretary Azar, On behalf of the Endocrine Society members and leaders, I write to offer our assistance as you lead the
More informationInformation for Vermont Prescribers of Prescription Drugs
Information for Vermont Prescribers of Prescription Drugs CADUET (amlodipine besylate/atorvastatin calcium) tablets This list does not imply that the products on this chart are interchangeable or have
More informationMagellan Rx. A smarter approach to pharmacy benefits management
Magellan Rx A smarter approach to pharmacy benefits management Presented by: Cheri Caruso, VP of Sales, Magellan Rx Management Bryce Canfield, VP, Client Development, GoodRx A unique vision of care We
More informationDaiichi Sankyo, Inc. (DSI)
Daiichi Sankyo, Inc. (DSI) Outlook for U.S. Business for 2009 Nov. 7 th, 2007 Joseph P. Pieroni President and CEO Daiichi Sankyo, Inc. Largest Pharmaceutical markets $300 $274.4 Annual Sales (US$ billions)
More informationManaged Care Trends in Statin Usage GARY R. BAZALO, MS, MBA
PHARMACY UTILIZATION Managed Care Trends in Statin Usage GARY R. BAZALO, MS, MBA ABSTRACT Purpose HMG-CoA reductase inhibitors ( statins ) have become the drug class of choice for the treatment of hyperlipidemia.
More informationJOIN IN AN UNPRECEDENTED STATEWIDE MOVEMENT TO CHANGE HEALTHCARE
JOIN IN AN UNPRECEDENTED STATEWIDE MOVEMENT TO CHANGE HEALTHCARE PASBO S STATEWIDE DATA STRATEGY WITH INNOVU PASBO 62 ND ANNUAL CONFERENCE AND EXHIBITS, PITTSBURGH 1 DATA STRATEGY PLATFORM 2 1 WHAT ARE
More informationMerrill Lynch conference. Matthew Emmens, CEO Shire plc September 20, 2007
Merrill Lynch conference Matthew Emmens, CEO Shire plc September 20, 2007 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical
More informationUpdate to HMO Drug Formulary Tier Definitions. February 8, 2018
Update to HMO Drug Formulary Tier Definitions February 8, 2018 Agenda 1 Overview of Current Drug Tiers 2 Proposed Drug Tiers for 2019 3 Impact to SFHSS and SFHSS Members 4 How the Drug Formulary Works
More informationAppendix C CHANGING THE TRAJECTORY:
Appendix C CHANGING THE TRAJECTORY: Impact of a Hypothetical Treatment That Slows the Progression of Alzheimer s In addition to the delayed onset scenario discussed in the report, another potential scenario
More informationEvaluation of Specialty Pharmacy in an Integrated Health-System
Evaluation of Specialty Pharmacy in an Integrated Health-System Emma Chermely, PharmD, BCACP Alyssa McCann, PharmD, BCACP *The presenters have no conflicts of interest to disclose. Objectives Introduce
More informationInformation for Vermont Prescribers of Prescription Drugs
Information for Vermont Prescribers of Prescription Drugs LIPITOR (atorvastatin calcium) tablets This list does not imply that the products on this chart are interchangeable or have the same efficacy or
More informationREFERENCE CODE GDHC109PIDR PUBLICAT ION DATE MAY 2015 FIBROMYALGIA GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC109PIDR PUBLICAT ION DATE MAY 2015 FIBROMYALGIA GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Fibromyalgia: Key Metrics in Seven Major Pharmaceutical Markets, 2013
More informationIslamic Republic of Iran
Islamic Republic of Iran prices, availability, affordability and price components prices matter Rapidly rising costs of health care and high medicine prices are a growing concern worldwide, especially
More informationPBMs: Impact on Cost and Quality of Pharmaceutical Care in the U.S.
Speaker Brian K. Solow, MD, FAAFP Optum Life Sciences Irvine, CA, USA PBMs: Impact on Cost and Quality of Pharmaceutical Care in the U.S. Brian K. Solow, MD, FAAFP Chief Medical Officer, Optum Life Sciences
More informationGenetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School
Genetics in Cancer Therapy Raju Kucherlapati, Ph.D. Harvard Medical School RK Financial interests I do not intend to discuss an off-label use of a product during this activity AVEO Pharmaceuticals KEW
More informationMedication trends shaping workers compensation. A 2018 mid-year review of the prevailing industry influences impacting pharmacy outcomes
Medication trends shaping workers compensation A 2018 mid-year review of the prevailing industry influences impacting pharmacy outcomes OPTUM WORKERS COMPENSATION DATA SET Analysis of our data, the industry
More informationShanghai. China. Medicine prices, availability and affordability
Shanghai China Medicine prices, availability and affordability Medicine prices matter Rapidly rising costs of health care and high medicine prices are a growing concern worldwide, especially in developing
More informationWalgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs
Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion
More informationCost of Mental Health Care
Section 4 Cost of Mental Health Care Per capita mental health spending for Americans with a mental health diagnosis has increased among children, peaking in. For adults, the spending has been more stable.
More information5/8/2017. Clinical Pharmacy Specialist Division of Kidney Disease and Hypertension
Clinical Pharmacy Specialist Division of Kidney Disease and Hypertension Clinical Assistant Professor Adjunct Clinical Associate Professor Pharmacy Practice 1 http://ed.ted.com/lessons/how-do-your-kidneys-work-emma-bryce.
More informationBig Data & Predictive Analytics Case Studies: Applying data science to human data Big-Data.AI Summit
Big Data & Predictive Analytics Case Studies: Applying data science to human data 1.03.2018 Big-Data.AI Summit Dr. Arnim Jost, Commercial Director Technology Copyright 2017 IQVIA. All rights reserved.
More informationMedication Therapy Management: Improving Health and Saving Money
Medication Therapy Management: Improving Health and Saving Money Ed Staffa, RPh Vice President, Pharmacy Mirixa Corporation estaffa@mirixa.com July 23, 2008 MTM At A Glance The U.S. health care system
More information2017 Drug Trends Series
2017 Drug Trends Series Part 1 Evaluating the traditional view Retail and mail-order prescriptions Published April 2018 1 2017 Drug Trends Series Traditional View First Script A year of important progress
More informationPrescription Drug Benefit Rider V
Prescription Drug Benefit Rider V Your Certificate of Coverage is amended as described in this document. This Rider becomes a part of your Certificate of Coverage and is subject to all provisions of your
More informationSpending on Individuals with Type 1 Diabetes and the Role of Rapidly Increasing Insulin Prices
Spending on Individuals with Type 1 Diabetes and the Role of Rapidly Increasing Insulin Prices Authors: Jean Fuglesten Biniek William Johnson January 2019 Insulin Prices Were the Primary Driver of Rapid
More informationBRIC DIABETES DRUGS MARKET
BRIC DIABETES DRUGS MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d M a
More informationI n t r o d u c t i o n t o t h e P h a r m a c e u t i c a l I n d u s t r y
I n t r o d u c t i o n t o t h e P h a r m a c e u t i c a l I n d u s t r y U n i v e r s i t y J o i n s I n d u s t r y M a r c h 1 5, 2 0 1 7 J a v i e r T o r r e j ó n Topics to be covered today..
More informationQ Update Tracking the Effect of the Economic Crisis on Pharmaceutical Consumption, Expenditures
Q4 2009 Update Tracking the Effect of the Economic Crisis on Pharmaceutical Consumption, Expenditures and Unit Prices Executive Summary The WHO, in collaboration with IMS, has put in place a programme
More informationPharmaceutical Biotechnology The Needs and Challenges of Innovation. Dr. Thomas Schreitmueller, Regulatory Policy, Biologics
Pharmaceutical Biotechnology The Needs and Challenges of Innovation Dr. Thomas Schreitmueller, Regulatory Policy, Biologics F. Hoffmann La Roche Ltd., Basel, Switzerland Innovation for unmet medical needs
More informationJukti Kumar Kalita, PhD Business Analytics and Insights Pfizer Presented at:
Hospital to Retail Spillover Analysis and Its Impact on Commercial Decision Making Jukti Kumar Kalita, PhD Business Analytics and Insights Pfizer Presented at: 1 Disclaimer The information provided and
More informationMArch The 2014 Drug Trend Report MEDICARE
MArch 2015 The 2014 Drug Trend Report MEDICARE content MedicaRE 3 Medicare Year in Review A Look at Medicare Overall Drug Trend for 2014 Medicare: Traditional Therapy Classes and Insights Top 10 Medicare
More informationREFERENCE CODE GDHC317DFR PUBLICAT ION DATE DECEMBER 2013 LUCENTIS (MICROVASCULAR COMPLICATIONS OF DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC317DFR PUBLICAT ION DATE DECEMBER 2013 LUCENTIS Executive Summary The table below presents a summary of the key metrics for Lucentis (Microvascular Complications for Diabetes) for recombinant
More informationScope and Methodology Size and Growth of the Market Issues and Trends Affecting the Rx-to-OTC Switches Market Leading Competitors
TABLE OF CONTENTS CHAPTER ONE: EXECUTIVE SUMMARY Scope and Methodology Size and Growth of the Market Issues and Trends Affecting the Rx-to-OTC Switches Market Leading Competitors CHAPTER TWO: INTRODUCTION
More informationPHARMACEUTICALS: Their Role in the Cost of Health Care
PHARMACEUTICALS: Their Role in the Cost of Health Care Pennsylvania Health Care Cost Containment Council 225 Market Street, Suite 400 Harrisburg, PA 17101 Phone: (717) 232-6787 Fax: (717) 232-3821 http://www.phc4.org
More informationCovered California Formulary Analysis of Top 100 Drugs and Select Classes Prepared for the California HealthCare Foundation Avalere.
Covered California Formulary Analysis of Top 100 Drugs and Select Classes Prepared for the California HealthCare Foundation 2015 Avalere.com About the Researchers ABOUT THE CALIFORNIA HEALTHCARE FOUNDATION
More informationPharmacy and Medical Guideline Updates
STAT Bulletin PO Box 15013 Albany, New York 12212 August 2, 2010 Volume 8: Issue 19 To: All PCPs and Specialists Contracts Affected: All Lines of Business Pharmacy and ical Guideline Updates As a result
More informationThe Impact of Tiered Co-Pays A Survey of Patients and Pharmacists
The Impact of Tiered Co-Pays A Survey of Patients and Pharmacists Research Report Conducted by Harris Interactive September, 2003 This study was completed on behalf of and with support from the National
More informationSpecialty drugs are a significant cost trend driver for
2009 Drug Utilization and Cost Trends: Tumor Necrosis Factor Inhibitors Drug Trends Anna A. Theodorou, RPh, MBA; Kelly M. Johnson, MBA; and John A. Szychowski, AAS, BS Specialty drugs are a significant
More informationPharmacy benefit guide
FlexRx SM 5-Tier Pharmacy benefit guide 1 Welcome to FlexRx The NHP FlexRx SM program is built for choice, savings, and convenience with benefits including: Low-cost drug tier for many common medications
More informationNational Dental Expenditure Flat Since 2008, Began to Slow in 2002
National Dental Expenditure Flat Since 2008, Began to Slow in 2002 Author: Marko Vujicic, Ph.D. The Health Policy Institute (HPI) is a thought leader and trusted source for policy knowledge on critical
More informationSPECIALTY PHARMACY Master Clinical Drug List
Abraxane J9264 Provider ONCOLOGY None NO Actemra J3262 Provider ARTHRITIS PA - all YES Acthar HP Gel J0800 Prov/Self Med/Pharm ENDOCRINE/METABOLIC PA - all YES Adagen J2504 Provider ENZYME DISORDERS None
More informationPrescription drug expenditures are the most rapidly growing component
Changing Prescribing Patterns and Increasing Prescription Expenditures in Medicaid Kenneth S. Fink, MD, MGA, MPH 1 Patricia J. Byrns, MD 2 1 Department of Family Medicine, University of North Carolina
More informationPrescription Drug Benefit Rider
Prescription Drug Benefit Rider Your Certificate of Coverage is amended as described in this document. This Rider becomes a part of your Certificate of Coverage and is subject to all provisions of your
More informationRealized Savings from Generic Drugs in Upstate New York
T H E F A C T S A B O U T Realized Savings from Generic Drugs in Upstate New York More Than $130 Million Saved in 2006 Compared With 2005 Finger Lakes Region Estimated generic savings: $29 million Generic
More informationThe power of partnership.
School Board of Clay County and UnitedHealthcare. Building health ownership together. December 13, 2017 Annual Healthplan Performance Review October 1, 2016 thru September 30, 2017 Let s get started inspiring
More informationPer Capita Health Care Spending on Diabetes:
Issue Brief #10 May 2015 Per Capita Health Care Spending on Diabetes: 2009-2013 Diabetes is a costly chronic condition in the United States, medical costs and productivity loss attributable to diabetes
More informationJanuary 16, Dear Administrator Verma:
Ms. Seema Verma Administrator Centers for Medicare and Medicaid Services Department of Health and Human Services Attention: CMMI New Direction P.O. Box 8011 Baltimore, MD 21244-1850 Re: (CMS-4182-P) Medicare
More informationCoverage Period: Coverage for: Plans: This is only a summary of your GatorCare pharmacy benefits. Coinsurance: you your Dependent Copayment: you
This is only a summary of your GatorCare pharmacy benefits. If you would like detail about your coverage and costs, you can get the complete terms in the policy or plan document at gatorcare.magellanrx.com/member
More informationTable 1: Price increases for Brand Name Drugs with Generic Equivalents
Table 1: Price increases for Brand Name Drugs with Generic Equivalents Brand Name Medication and Dose Total % Change Since 10/2012 ACTOS 15 MG TABLET 6.36 11.03 73.39% ACTOS 30 MG TABLET 9.7 16.80 73.23%
More informationFlexRx 6-Tier. SM Pharmacy Benefit Guide
FlexRx 6-Tier SM Pharmacy Benefit Guide Welcome to FlexRx The AllWays Health Partners FlexRx SM program is built for choice, savings, and convenience with benefits including: Low-cost drug tier for many
More informationCoverage Period: 01/01/ /31/2018 Coverage for: Individual and/or Family Plan: Healthy Rewards HSA
This is only a summary of your GatorCare pharmacy benefits. If you would like detail about your coverage and costs, you can get the complete terms in the policy or plan document at gatorcare.magellanrx.com/member
More informationOncology Treatment Trends and Implications for Future Drug Development In China. Presented by Stephanie Hawthorne 16 April 2013
Oncology Treatment Trends and Implications for Future Drug Development In China Presented by Stephanie Hawthorne 16 April 2013 Economic development, demographic shift, regulatory environment change, industry
More informationStatement Of. The National Association of Chain Drug Stores. For. U.S. Senate Finance Committee. Hearing on:
Statement Of The National Association of Chain Drug Stores For U.S. Senate Finance Committee Hearing on: 10:30 a.m. 215 Dirksen Senate Office Building National Association of Chain Drug Stores (NACDS)
More informationMedicare Severity-adjusted Diagnosis Related Groups (MS-DRGs) Coding Adjustment
American Hospital association December 2012 TrendWatch Are Medicare Patients Getting Sicker? Today, Medicare covers more than 48 million people, and that number is growing rapidly baby boomers are reaching
More information